




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 1G




FIG. 1H




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A

Binding of IL2-variants at 18nM to CD25, CD122






FIG. 3B






FIG. 5B

FIG. 5A




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7B




FIG. 7D




FIG. 7A




FIG. 7C




FIG. 7E

FIG. 7F




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C





FIG. 9D


CD8+ Proliferation: 0.4 nM Test Article



Not Blocked

FIG. 10A


CD4+ Proliferation: 0.4 nM Test Article



Not Blocked

FIG. 10B


CD8+ Proliferation: 0.4 nM Test Article



Pre-Blocked with Pembrolizumab

FIG. 10C

CD4+ Proliferation: 0.4 nM Test Article



Pre-Blocked with Pembrolizumab

FIG. 10D




FIG. 11

IL2 Trans-activation of CD8 T-cells




FIG. 12A

IL2 Trans-activation of CD4 T-cells




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E




FIG. 13F




FIG. 13G




FIG. 13H




FIG. 13I




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F




FIG. 14G




FIG. 14H




FIG. 15